- Language: English
- Published: May 2013
- Region: Europe
Global Plasma Market 2012-2016
- Published: March 2013
- Region: Global
- 44 Pages
- Infiniti Research Limited
This report forecasts the Global Plasma market to grow at a CAGR of 10.31 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in the aging population. The Global Plasma market has also been witnessing the trend of increasing market consolidation. However, stringent regulations could pose a challenge to the growth of this market.
This report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global plasma market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space CSL Behring LLC, Baxter International Inc., Grifols S.A., and Octapharma AG
Other vendors mentioned in the report are Kedrion S.p.A., Biotest AG, Sanguine Corp., Cangene bioPharma Inc., Haemacure Corp., Kamada Inc., Omrix Biopharmaceuticals Inc., Vivostat A/S, Pfizer Inc., AstraZeneca plc, Takeda Pharmaceutical Inc., Novo Nordisk A/S, sanofi S.A., China Biologic Products Inc., Beijing Tiantan Biological Products Co. Ltd., Bharat Serums and Vaccines Ltd., and LFB Group.
Key questions answered in this report:
- What will the market size be in 2016 and at what will be the growth rate?
- What are key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by key vendors?
- What are the strengths and weaknesses of each of these key vendors? SHOW LESS READ MORE >
01. Executive Summary
03. Market Coverage
04. Market Landscape
04.1Market Size and Forecast
04.2Global Plasma Market by Plasma Derivative Segmentation
04.3Five Force Analysis
05. Geographical Segmentation
06. Vendor Landscape
06.1Global Plasma Market
06.2Global Immunoglobulin Market
06.3Global Albumin Market
Product Portfolio Matrix
07. Buying Criteria
08. Market Growth Drivers
09. Drivers and their Impact
10. Market Challenges
11. Impact of Drivers and Challenges
12. Market Trends
13. Key Vendor Analysis
13.1 Baxter International Inc.
13.2 CSL Behring LLC
13.3 Grifols S.A.
13.4 Octapharma AG
14. Other Reports in this Series
List of Exhibits:
Exhibit 1: Composition of Blood Plasma
Exhibit 2: Global Plasma Market 2012-2016 (US$ billion)
Exhibit 3: Global Plasma Market by Plasma Derivative Segmentation
Exhibit 4: Global Plasma Market by Plasma Derivative Segmentation 2012
Exhibit 5: Global Plasma Market by Geographical Segmentation 2012
Exhibit 6: Global Plasma Market by Vendor Segmentation 2012
Exhibit 7: Global Immunoglobulin Market by Vendor Segmentation 2012
Exhibit 8: Global Albumin Market by Vendor Segmentation 2012
Exhibit 9: Business Segmentation of Baxter International Inc.
Exhibit 10: Business Segmentation of Grifols S.A.
Exhibit 11: Business Segmentation of Octapharma AG
This report Global Plasma Market 2012-2016 is based on an in-depth analysis covering the Americas, the EMEA region, and the APAC region. The report aims to aid decision makers' understanding of the present and future landscape of the market.
Commenting on the report, an analyst from TechNavio's Healthcare team said: 'Over the years, the Global Plasma market has been witnessing significant consolidation and as a result the positions of the leading players have shifted dramatically over the past decade. This trend is expected to continue during the forecast period as vendors attempt to strengthen or hold their market position. Market consolidation has resulted in stronger competitors that are better able to compete as sole-source vendors to end-users. For instance, Australia-based CSL Behring has become one of the world's leading fractionators through a series of acquisitions including its 2000 buyout of ZLB Behring and 2004 purchase of Aventis Behring. Grifols acquisition of Talecris Biotherapeutics has further consolidated the industry.'
According to the report, one of the major drivers is the increase in the aging population, which will lead to an increase in the number of immune deficiency patients.
Further, the report states that one of the most important challenges in the market is the stringent regulations with respect to the selection of donors, plasma screening process, and fractionation process.
The report also includes a discussion of the key vendors operating in this market. The key vendors dominating this market space are Baxter International Inc., CSL Behring LLC, Grifols S.A., and Octapharma AG.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
- Grifols S.A.
- Baxter International Inc.
- CSL Behring LLC.
- Octapharma AG
- Kedrion S.p.A.
- Biotest AG
- Bio Products Laboratory Ltd.
- Cangene bioPharma Inc.
- Kamada Inc.
- Chin Biologic Products Inc.
- Vivostat A/S
- Beijing Tiantan Biological Products Co. Ltd.
- Shanghai RAAS Blood Products Co. Ltd.
- LFB Group
- Novo Nordisk A/S
- Beijing Tiantan Biological Products Co. Ltd.
- Omrix Biopharmaceuticals Inc.